"The kidney isn't one target. It's really dozens of highly specialized targets packed into one organ." Our CEO joined @biospace's Denatured to discuss what that means for cell and gene therapy in #KidneyDisease. bit.ly/4zchZI1 #CKD #CellTherapy #GeneTherapy

Our final #KidneyWk posters will be presented this morning, including two that follow rilparencel, our investigational cell therapy, through manufacturing. Thank you to everyone who has stopped by this week.

Leading clinical researcher Katherine Tuttle, MD, joins CEO Bruce Culleton, MD + R&D Head Anthony Conway, PhD, to discuss new research on our investigational cell therapy, and the evolving #CKD treatment landscape. Live Q&A will follow. Register: bit.ly/4Bob3Ja

Today at #KidneyWk: a pooled Phase 2 analysis and a manufacturing poster this morning (10 AM–12 PM MDT), then our oral presentation at 5:40 PM in Mile High Ballroom 1D.

Our first two #KidneyWk posters will be presented this morning, both on studying CKD in human cells and tissue outside the body. Our team is at TH-PO1128 and TH-PO1129 until noon MDT.

We’re heading to Denver for @ASNKidney #KidneyWk to share new research on rilparencel, our investigational autologous cell therapy, including non-clinical research and a pooled analysis from our Phase 2 studies. Learn more ↓

How might cell therapy work in CKD? At #KidneyWk, we’ll share 8 abstracts exploring that question, from non-clinical CKD models, drug product characterization, and more. investors.prokidney.com/news… #CKD #CellTherapy

For people with advanced #CKD, the biggest threat is often cardiovascular disease, not kidney failure. On #WorldHeartDay, we're recognizing the close connection between heart and kidney health. #KidneyHealth

The risk factors highlighted during #CholesterolEducationMonth, including diabetes, high blood pressure and metabolic disease, are also leading drivers of #CKD. Because CKD often develops without symptoms, many people don't know they have it. Learn more: bit.ly/4hhezMl

Our Boston team assembled nutritional starter kits for CKD patients across New England — recipe cards, measuring spoons, jar openers, educational materials and more. Thanks to @NKFNewEngland for bringing the ingredients and for everything they do for #CKD patients. #KidneyHealth

Orange pom-poms, catch on the field, and Sidney the Kidney. Thanks to @WSDashBaseball and @nkfcarolinas for a great Sunday at Truist Stadium, and for the kidney health resources they shared with fans all afternoon. #KidneyHealth #WinstonSalem

Dialysis often means three to four hours in a chair, three times a week, then feeling too exhausted to work. On the Vanguards of Health Care podcast, our CEO on why ProKidney focuses on preserving kidney function. bit.ly/4xk1sQX #CKD #KidneyHealth

Sunday Fun Day at Truist Stadium this weekend. Our team will be there with @WSDashBaseball and @nkfcarolinas, who’ll be there with kidney health resources on site. A portion from every ticket purchased through their link supports NKF’s work in NC. #KidneyHealth #WinstonSalem

#CKD therapies like SGLT2 inhibitors, finerenone and GLP-1 RAs have given patients more ways to slow progression. Rilparencel, our investigational cell therapy, is being studied as a potential addition.

Today is National Patient Advocacy Day. In kidney care, advocates help patients understand their options, find resources and make their voices heard. So much in #CKD is learned from patients themselves. To everyone standing alongside them, thank you. #KidneyHealth

August is National Minority Donor Awareness Month. More than 100,000 people in the US are waiting for a transplant, and 60% are from racial and ethnic minority communities. A reminder of why registration and equitable access matter. #KidneyHealth

New on @BBGIntelligence's Vanguards of Health Care: our CEO Bruce Culleton, MD on advanced #CKD, why patients still progress despite better care and how rilparencel, our investigational cell therapy, aims to preserve function. bit.ly/4xk1sQX

Big moment for our team: a group of well-deserved promotions across ProKidney. 👏 These are the people turning bold science into real progress for patients with advanced CKD and type 2 diabetes — and raising the bar every step of the way. #TeamProKidney #BiotechCareers

Most #CKD therapies aim to slow progression. Rilparencel, our investigational cell therapy, takes a different approach, using a patient’s own kidney cells to help preserve function. Learn more about our clinical trial: hopeforckd.com/ #ClinicalTrials #KidneyHealth

This #ChronicDiseaseDay: chronic kidney disease is one of the most common chronic conditions, affecting millions of Americans. In advanced #CKD, the goal is preserving kidney function, which drives the work we do every day. Learn more: prokidney.com/our-technology